Top

Published in:

01-03-2017 | Original Article

Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis

Authors: Xiaohui Hu, Yan Yang, Daokai Gong

Published in: Neurological Sciences | Issue 3/2017

Abstract

As a biomarker of axonal injury, neurofilament light chain (NFL) in multiple system atrophy (MSA) patients and Parkinson’s disease (PD) patients has been investigated by numerous studies. However, cerebrospinal fluid (CSF) NFL changes are conflicting in MSA patients relative to PD patients to date. Therefore, the current study was carried out to find out possible heterogeneity sources. Furthermore, “Neurofilament”, “Neurofilament light chain” and “Multiple system atrophy” were employed to search “PubMed”, “Springer” and “Medline” databases until August 2016 with standard mean difference (Std.MD) being calculated. In addition, subgroup analysis and meta-regression were performed to assess possible heterogeneity sources. Nine studies were pooled, in which 212 MSA patients and 373 PD patients were involved. Moreover, CSF NFL in MSA patients was higher than that in PD patients [pooled Std.MD = 1.56, 95% CI (1.12, 2.00), p < 0.00001] with significant heterogeneity (I ² = 76%). Besides, population variations, sample size, the difference in CSF phosphorylated tau (p-tau) levels between MSA patients and PD patients, and Hoehn–Yahr staging of PD patients were the main heterogeneity sources. As shown by meta-regression, Hedges’s g of CSF NFL was correlated with CSF Std.MD of α-synuclein between MSA patients and healthy controls (r = −1.34824, p = 0.00025). Therefore, CSF NFL increased in MSA patients relative to PD patients. Meta-regression showed that NFL was associated with α-synuclein in CSF of MSA patients relative to healthy controls. Due to the influence of heterogeneity sources, more prospective large sample studies are still needed to assess CSF NFL changes in MSA patients relative to PD patients.

Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL (2013) Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease. Brain Pathol 23:263–273CrossRefPubMed

Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T et al (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38:4–24CrossRefPubMed

Stefanova N, Bucke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178CrossRefPubMed

Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK (2012) Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol 124:51–65CrossRefPubMedPubMedCentral

Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W et al (2014) Towards translational therapies for multiple system atrophy. Prog Neurobiol 118:19–35CrossRefPubMedPubMedCentral

Shimohata T, Aizawa N, Nakayama H, Taniguchi H, Ohshima Y, Okumura H et al (2016) Mechanisms and prevention of sudden death in multiple system atrophy. Parkinsonism Relat Disord 30:1–6CrossRefPubMed

Sako W, Murakami N, Izumi Y, Kaji R (2014) The difference in putamen volume between MSA and PD: evidence from a meta-analysis. Parkinsonism Relat Disord 20:873–877CrossRefPubMed

Wang PS, Wu HM, Lin CP, Soong BW (2011) Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy. Neuroradiology 53:471–481CrossRefPubMed

Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A et al (2015) Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol Dis 80:29–41CrossRefPubMed

10.

Bäckström DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M et al (2015) Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurol 72:1175–1182CrossRefPubMed

11.

Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson’s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352:84–87CrossRefPubMed

12.

Sterne J, Moher D, and (editors)(2011) Chapter 10:addressing reporting biases.2011.In:Cochrane hand-book for systematic reviews of intervention version 510(updated March 2011)[Internet]. The Cochrane Collaboration Available from www.cochrane-handbool.org

13.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed

14.

Holmberg B, Rosengren L, Karlsson JE, Johnels B (1998) Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov Disord 13:70–77CrossRefPubMed

15.

Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L (2001) CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 8:23–31CrossRefPubMed

16.

Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging 28:742–747CrossRefPubMed

17.

Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B (2010) Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 16:142–145CrossRefPubMed

18.

Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jorgensen HL et al (2012) Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 18:69–72CrossRefPubMed

19.

Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69:1445–1452CrossRefPubMed

20.

Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RA, Bloem BR et al (2015) CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol 6:91. doi:10.3389/fneur.2015.00091 CrossRefPubMedPubMedCentral

21.

Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86:1240–1247CrossRefPubMedPubMedCentral

22.

Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE et al (2014) Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34:12368–12378CrossRefPubMed

23.

Shea TB, Lee S (2011) Neurofilament phosphorylation regulates axonal transport by an indirect mechanism: a merging of opposing hypotheses. Cytoskeleton (Hoboken) 68:589–595CrossRef

24.

Teunissen CE, Khalil M (2012) Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 18:552–556CrossRefPubMed

25.

Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A et al (2015) Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 86:273–279CrossRefPubMed

26.

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA et al (2016) Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91:56–66CrossRefPubMed

27.

Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A et al (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2:748–755CrossRefPubMedPubMedCentral

28.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al (2013) Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70:1277–1287PubMedPubMedCentral

29.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study. Acta Neuropathol 131:935–949CrossRefPubMed

Title: Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis
Authors: Xiaohui Hu
Yan Yang
Daokai Gong
Publication date: 01-03-2017
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 3/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-016-2783-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Cavernous sinus syndrome due to neurosarcoidosis in adolescence: a diagnosis not to be missed

Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series

Muscle elastography: a new imaging technique for multiple sclerosis spasticity measurement

Camptocormia as an onset symptom of myasthenia gravis

Steroid-responsive hyperammonemic encephalopathy as first manifestation of multiple myeloma

Ultra-high magnetic resonance imaging (MRI): a potential examination for deep brain stimulation devices and the limitation study concerning MRI-related heating injury